- Trials with a EudraCT protocol (33)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
33 result(s) found for: Emission reduction.
Displaying page 1 of 2.
EudraCT Number: 2016-003343-11 | Sponsor Protocol Number: GLP1ALCOHOL | Start Date*: 2017-04-12 | |||||||||||
Sponsor Name:Psychiatric Centre Copenhagen | |||||||||||||
Full Title: Does Glucagon-like Peptide 1 (GLP-1) receptor stimulation reduce alcohol intake in patients with alcohol dependence? | |||||||||||||
Medical condition: Alcohol dependence | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020472-34 | Sponsor Protocol Number: IEO S542/310 | Start Date*: 2010-12-14 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: 18F-Fluorothymidine Positron Emission Tomography as an early predictor of response to neoadjuvant therapy in patients with locally advanced breast carcinoma | |||||||||||||
Medical condition: Breast carcinoma classified as cT1b,c, T2, T3, or cT4 a-c, cN0-2, N3, M0 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003280-38 | Sponsor Protocol Number: PSY-NIL-0006 | Start Date*: 2016-05-04 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Positron Emission Tomography assessment of Ketamine Binding of the Serotonin Transporter and its Relevance for Rapid Antidepressant Response | |||||||||||||
Medical condition: 20 patients with severe unipolar depression (structured clinical interview for DSM-IV and the 17-item Hamilton Depression Rating Scale), also 20 age and sex matched healthy controls. plus 12 HC f... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004349-35 | Sponsor Protocol Number: 7001 | Start Date*: 2021-02-02 | |||||||||||
Sponsor Name:Klinisk Forskningsenhed, Medicinsk Afdeling, Hæmatologisk Afsnit, Sygehus Lillebælt, Vejle Sygehus | |||||||||||||
Full Title: Melphalan flufenamide (melflufen) and Dexamethasone re-induction in Daratumumab-refractory Multiple Myeloma as an Adjunct to Continued Daratumumab (MERMAID) | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000381-11 | Sponsor Protocol Number: CCMK389X2201 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sar... | |||||||||||||
Medical condition: Chronic pulmonary sarcoidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000794-31 | Sponsor Protocol Number: October2011,version5 | Start Date*: 2011-06-15 | |||||||||||
Sponsor Name:Dept. of Pharmacology | |||||||||||||
Full Title: Neurodegenerative Changes in Alzheimer’s Disease: Identifying potential effects of Victoza® on degenerative changes | |||||||||||||
Medical condition: Alzheimer's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004078-24 | Sponsor Protocol Number: SARIPET_2019.099_version_1.1 | Start Date*: 2020-05-07 | |||||||||||
Sponsor Name:IDIVAL | |||||||||||||
Full Title: Effect of Sarilumab on atherosclerotic disease measured by PET/CT (Positron Emission Tomography/Computed Tomography) in Rheumatoid Arthritis | |||||||||||||
Medical condition: RHEUMATOID ARTHRITIS | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005246-59 | Sponsor Protocol Number: EO1115 | Start Date*: 2016-03-23 | |||||||||||
Sponsor Name:Michael Patrick Achiam | |||||||||||||
Full Title: Endoscopic electroporation in esophageal cancer | |||||||||||||
Medical condition: Esophageal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001200-20 | Sponsor Protocol Number: CSET 1287 | Start Date*: 2007-06-01 |
Sponsor Name:Institut Gustave Roussy | ||
Full Title: A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer | ||
Medical condition: adenocarcinoma of the biliary tract ( gallbladder, intra and/ or extrahepatic bile ducts, ampulla of Vater) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005462-30 | Sponsor Protocol Number: MDCO-APO-14-01 | Start Date*: 2016-10-26 |
Sponsor Name:The Medicines Company | ||
Full Title: A multiple dose, dose-finding, placebo controlled, double blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and evaluate the effi... | ||
Medical condition: acute coronary syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-000826-13 | Sponsor Protocol Number: MDCO-APO-15-01 | Start Date*: 2016-01-20 |
Sponsor Name:The Medicines Company | ||
Full Title: A placebo-controlled, double-blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and to evaluate the efficacy, pharmacokinetics, sa... | ||
Medical condition: acute coronary syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) HU (Completed) NL (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002855-25 | Sponsor Protocol Number: EIP-VX00-745-302 | Start Date*: 2015-03-11 | |||||||||||
Sponsor Name:EIP Pharma, LLC | |||||||||||||
Full Title: A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic ... | |||||||||||||
Medical condition: Alzheimer’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004970-16 | Sponsor Protocol Number: CS15-033 | Start Date*: 2017-05-30 | |||||||||||
Sponsor Name:Medizinische Universität Wien | |||||||||||||
Full Title: Imaging the functional and molecular impact of poly-unsaturated fatty acids on dopamine-dependent cognitive functions: a combined [11C]-(+)-PHNO PET/MRI study at different stages of cognitive impai... | |||||||||||||
Medical condition: This study will assess the effects of poly-unsaturated fatty acids on working memory (measured using an n-back test) in healthy volunteers, in subjects who are at high risk for developing a psychot... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002557-29 | Sponsor Protocol Number: SK_DMDPA-03 | Start Date*: 2021-10-25 | |||||||||||
Sponsor Name:Synektik Spółka Akcyjna | |||||||||||||
Full Title: A Phase III Study of [11C]-DMDPA Tracer for Positron Emission Tomography PET-CT Myocardial Perfusion Imaging (MPI). | |||||||||||||
Medical condition: Known or suspected acute coronary syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003760-30 | Sponsor Protocol Number: EMR63325-021 | Start Date*: 2014-04-30 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled phase III trial of tecemotide versus placebo in subjects with completed concurrent chemo-radiotherapy for unresectable stage III non-smal... | |||||||||||||
Medical condition: unresectable stage III non-small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) AT (Completed) BE (Completed) DE (Prematurely Ended) SE (Completed) PT (Completed) IT (Completed) IE (Completed) SK (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005422-35 | Sponsor Protocol Number: | Start Date*: 2015-05-28 | |||||||||||
Sponsor Name:Imperial College London-Imperial College Healthcare NHS Trust | |||||||||||||
Full Title: THE ROLE OF BUSPIRONE IN ATTENUATING LEVODOPA-INDUCED DYSKINESIAS IN PATIENTS WITH PARKINSON'S DISEASE: A CLINICAL AND POSITRON EMISSION TOMOGRAPHY STUDY WITH 11C-PHNO. | |||||||||||||
Medical condition: Levodopa induced dyskinesias within Parkinson's disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001245-32 | Sponsor Protocol Number: PGX-III-AP-002 | Start Date*: 2011-10-19 | |||||||||||
Sponsor Name:Forest Laboratories, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) | |||||||||||||
Medical condition: Coronary Artery Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004530-38 | Sponsor Protocol Number: ASSTBS-FARONCO-PESETA-20 | Start Date*: 2022-05-30 | |||||||||||
Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: PROSPECTIVE, PHASE II STUDY TO EVALUATE THE EFFICACY OF ADDITION OF PROGESTERONE TO STANDARD CHEMOTHERAPY ACCORDING TO EDP SCHEME PLUS MITOTANE IN PATIENTS WITH ADVANCED ADRENALCORTICAL (PESETA TRIAL) | |||||||||||||
Medical condition: advanced/ metastatic patients with ACC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000614-64 | Sponsor Protocol Number: VIRUSNET201401 | Start Date*: 2015-12-17 | |||||||||||
Sponsor Name:Department of Immunology, Genetics and Pathology (IGP), Rudbeck Laboratory, Uppsala University | |||||||||||||
Full Title: Study of recombinant adenovirus in patients with neuroendocrine neoplasms; safety and efficacy | |||||||||||||
Medical condition: Neuroendocrine neoplasms (NENs) is a heterogeneous group with varying symptoms, tumor biology and treatment response. NENs may occur in any organ, most commonly they are observed in the gastroente... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003307-62 | Sponsor Protocol Number: R1500-HTG-1522 | Start Date*: 2018-07-20 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy, Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk... | |||||||||||||
Medical condition: Severe Hypertriglyceridemia (sHTG) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
